

Freedom of Information Request

Ref: UHB 20-328

4 August 2020

By Email

Dear Sir/Madam

Thank you for your request for information under the Freedom of Information Act 2000. The Trust's response is as follows:

- We can confirm that we hold some the information you are requesting.

1. Please detail the number of patients currently prescribed apremilast with a current primary diagnosis of: a) Psoriasis b) Psoriatic Arthritis?

Psoriasis - 3

Psoriatic Arthritis - Pharmacy issues are not linked to diagnosis so do not record this information.

2. Of the patients prescribed apremilast in the last 12 months for Psoriasis and Psoriatic Arthritis, what number of patients received treatment with targeted small molecules or biologic therapies* prior to beginning treatment with apremilast? (*See annex 1 for a list of small molecule/biologic therapies)

Psoriasis -1

Psoriatic Arthritis - Pharmacy issues are not linked to diagnosis so do not record this information.

3. How many small molecule- and/or biologic-naive patients in the Trust are currently receiving a conventional non-biologic systemic therapy for Psoriasis or a conventional non-biologic disease-modifying anti-rheumatic drug (DMARD) for Psoriatic Arthritis? (e.g. methotrexate)

Therapy No. of patients receiving the specified therapy

Psoriasis Psoriatic Arthritis

Systemic therapies

Disease-modifying anti-rheumatic drugs (DMARDs)

Unable to answer – we have no way of tracking this data

4. Is CCG prior-approval required for the prescribing of apremilast? Y/N. If Yes, please tick the system you use: Blueteq /Other .

No

5. If other, what system do you use?

Not applicable, no prior approval process in place currently

**6. Is apremilast listed individually or grouped with biologic therapies on the prior-approval form for Psoriasis and Psoriatic Arthritis?
Psoriasis: Individually grouped Psoriatic Arthritis: Individually grouped .**

Not applicable, no prior approval process in place currently

7. Please provide the wording used on the CCG's prior-approval form for the prescribing of apremilast.

Psoriasis Psoriatic Arthritis

Please provide the wording used on the CCG's prior-approval form for the prescribing of apremilast

Not applicable, no prior approval process in place currently

This concludes our response. We trust that you find this helpful, but please do not hesitate to contact us directly if we can be of any further assistance.

If, after that, you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to:

Director of Corporate Governance
University Hospitals Bristol and Weston NHS Foundation Trust
Trust Headquarters
Marlborough Street
Bristol
BS1 3NU

Please remember to quote the reference number above in any future communications.

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF

Publication

Please note that this letter and the information included/attached will be published on our website as part of the Trust's Freedom of Information Publication Log. This is because information disclosed in accordance with the Freedom of Information Act is disclosed to the public, not just to the individual making the request. We will remove any personal information (such as your name, email and so on) from any information we make public to protect your personal information.

To view the Freedom of Information Act in full please click [here](#).

Yours sincerely

Freedom of Information Team
University Hospitals Bristol and Weston NHS Foundation Trust